Workflow
宏力医疗管理(09906) - 2022 - 中期财报
HONLIV HEALTHHONLIV HEALTH(HK:09906)2022-09-27 08:49

Financial Performance - Honliv Healthcare Management Group reported a revenue of HKD 150 million for the first half of 2022, representing a 20% increase compared to the same period in 2021[14]. - The company achieved a net profit of HKD 30 million, which is a 15% increase year-over-year[14]. - The group's total comprehensive income for the six months ended June 30, 2022, was RMB 374.7 million, an increase of RMB 88.3 million or 30.8% compared to RMB 286.4 million for the same period in 2021[21]. - Total revenue increased by 30.8% from RMB 286.4 million in the six months ended June 30, 2021, to RMB 374.7 million in the six months ended June 30, 2022[35]. - Net profit rose by 62.0% from RMB 20.0 million to RMB 32.5 million, with net profit margin improving from 7.0% to 8.7%[48]. - The company reported revenue of RMB 374,742 thousand for the six months ended June 30, 2022, representing a 30.8% increase from RMB 286,404 thousand for the same period in 2021[112]. - Operating profit increased to RMB 41,848 thousand, compared to RMB 35,509 thousand in the previous year, reflecting a growth of 18.5%[112]. - The net profit attributable to the company's owners for the six months ended June 30, 2022, was RMB 32,173 thousand, compared to RMB 19,823 thousand in the previous year, reflecting a growth of 62.1%[159]. Patient Services and Growth - User data indicates that the number of patients served increased by 25% to 50,000 in the first half of 2022[14]. - The company plans to expand its services into three new provinces in China by the end of 2023, aiming for a 30% growth in patient numbers[14]. - The total number of inpatient visits increased by 19.4% to 24,863, compared to 20,822 for the same period in 2021[22]. - Outpatient visits totaled 643,476, reflecting a growth of 9.5% from 587,413 in the previous year[23]. - Inpatient medical service revenue rose by 32.8% from RMB 136.4 million to RMB 181.2 million, driven by an increase in patient visits and average treatment costs[38]. - Outpatient medical service revenue increased by 29.0% from RMB 150.0 million to RMB 193.5 million, attributed to higher patient visits and average treatment costs[38]. Research and Development - Honliv is investing HKD 10 million in R&D for new healthcare technologies, focusing on telemedicine solutions[14]. - The group published 16 medical research papers, including 2 at the national level and 9 at the provincial level, during the reporting period[29]. Strategic Initiatives - A strategic partnership with a local hospital network was established to enhance service delivery and patient care[14]. - The company is exploring potential acquisitions of smaller healthcare facilities to expand its market presence[14]. - The group aims to enhance core competitiveness and brand influence while improving patient satisfaction throughout the medical service process[19]. - The group plans to expand its business scale through new construction and management output, aiming for group development[18]. Financial Health and Liquidity - The company reported a cash flow from operations of HKD 40 million, indicating strong liquidity and financial health[14]. - Current liabilities decreased by 81.1% from RMB 65.4 million to RMB 12.3 million, primarily due to cash inflows from operating activities[51]. - The company's debt decreased from RMB 187.0 million as of December 31, 2021, to RMB 160.0 million as of June 30, 2022, a reduction of RMB 27.0 million[55]. - The asset-liability ratio as of June 30, 2022, was 37.9%, down from 41.1% as of December 31, 2021[68]. - Cash generated from operating activities for the six months ended June 30, 2022, was RMB 51,454,000, an increase of 31.0% compared to RMB 39,262,000 in the same period last year[126]. - The company has taken measures to improve its financial position and alleviate liquidity pressure, including negotiations with banks for refinancing[136]. Cost Management - Honliv's management emphasized a commitment to improving operational efficiency, targeting a 10% reduction in costs by the end of 2022[14]. - Total sales costs increased by 33.1% from RMB 218.7 million to RMB 291.2 million, primarily due to higher drug and medical supplies costs[42]. - Administrative expenses increased by 7.9% from RMB 32.6 million to RMB 35.2 million, mainly due to higher employee benefits[45]. - Financial costs decreased by 99.8% from RMB 8.3 million to RMB 0.02 million, attributed to loan repayments and reduced interest expenses[46]. Shareholder Information - Major shareholders include Cao Junming with 74.00% and Rubrical Investment with 22.20% of shares[78]. - The company raised approximately HKD 264.8 million from the global offering by issuing 150 million shares at HKD 2.10 each[85]. - As of June 30, 2022, the company has utilized HKD 151.3 million of the raised funds, leaving HKD 113.5 million unutilized[86]. - 29.5% of the raised funds are allocated for the expansion of the company's first building, while 26.1% is for hospital acquisitions[86]. Compliance and Governance - The company has complied with all applicable corporate governance code provisions during the reporting period[95]. - The company has adopted a standard code for securities transactions by directors, with all directors confirming compliance during the reporting period[97].